Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 12:16:1387.
doi: 10.3332/ecancer.2022.1387. eCollection 2022.

Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer

Mariana Serrano  1 , Jhajaira M Araujo  2 , Cristian Pacheco  1 , Jackeline Macetas  1 , Mariella A Blum  3 , Alfredo Carrato  4 , Eloy Ruiz  5 , Francisco Berrospi  5 , Carlos Luque  5 , Ivan Chavez  5 , Eduardo Payet  1 , Luis Taxa  6 , Paola Montenegro  1
Affiliations

Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer

Mariana Serrano et al. Ecancermedicalscience. .

Abstract

Background: Gastric cancer (GC) is the fourth most common cause of cancer deaths around the world and the first cause of cancer deaths in Peru; however, there are no prospective trials for adjuvant chemotherapy in GC after curative gastrectomy in this country. The objective of this study was to evaluate the effectiveness of adjuvant chemotherapy in stage II-III gastric cancer patients who underwent D2 gastrectomy.

Methods: We included patients with stage II-III gastric cancer who underwent radical gastrectomy and D2 dissection between 2014 and 2016 at our institution. Patients received 3-week cycles of capecitabine (1,000 mg/m2 twice daily on days 1-14) plus oxaliplatin (130 mg/m2 on day 1) for 6 months. Survival curves were estimated with the Kaplan-Meier method, and the Cox proportional hazards model was used to identify prognostic factors for survival.

Results: In total, 173 patients were included: 100 (57.8%) patients received adjuvant chemotherapy and surgery (AChS) and 73 (42.2%) surgery alone (SA). Three-year disease-free survival (DFS) was higher in the AChS groups (69%) than in the SA group (52.6%) (p = 0.034). Regarding overall survival (OS), 31 patients (31%) died in the AChS group compared with 34 (46.6%) in the SA group (p = 0.027). In the multivariate analysis, adjuvant chemotherapy was an independent prognostic factor for DFS (HR = 0.60; 95% CI = 0.37-0.97; p = 0.036) and OS (HR = 0.58; 95% CI = 0.36-0.95; p = 0.029). ACh showed consistent benefit in DFS and OS for patients with albumin >3.5 g/dL, lymphovascular and perineural invasion, pT4, pN2-3, pathologic stage (PS) IIIA and IIIB and lymph node ratio (LNR) > 13.1.

Conclusion: These data suggest that adjuvant capecitabine and oxaliplatin reduce the recurrence and mortality in patients with stage II-III gastric cancer who underwent D2 gastrectomy. PS IIIA and IIIB and LNR > 13.1 benefited more from receiving adjuvant chemotherapy and poorly cohesive gastric carcinoma did not significantly reduce the rates of survival.

Keywords: adjuvant chemotherapy; gastric cancer; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1.
Figure 1.. Kaplan–Meier curves for (a): DFS and (b): OS.
Figure 2.
Figure 2.. Forest plot of the treatment effect on disease-free survival in specific subgroups.
Figure 3.
Figure 3.. Forest plot of the treatment effect on overall survival in specific subgroups.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer. 1993;55(6):891–903. doi: 10.1002/ijc.2910550604. - DOI - PubMed
    1. Howlader N, Noone AM, Krapcho M. SEER Cancer Statistics Review, 1975–2018. Bethesda: National Cancer Institute; 2021. [ https://seer.cancer.gov/csr/1975_2018/] based on November 2020 SEER data submission, posted to the SEER web site.
    1. Bernabé-Monsalve L. (Univ Nac Mayor San Marcos Lima-Perú) Prevalencia de Helicobacter pylori en el agua de consumo humano de pacientes diagnosticados con cáncer gástrico Helicobacter pylori positivo en el Instituto Nacional de Enfermedades Neoplásicas 2015–2016. 2017.
    1. Payet E. Registro de cáncer de Lima Metropolitana: Incidencia y mortalidad 2010–2012. 2016.

LinkOut - more resources